GnRH analogs in treating uterine leiomyomata and endometriosis.
The results of hormonal examinations, measurements of dimensions of the uterus and leiomyomas, body weight, and also frequency of incurred climacteric signs in patients treated with Decapeptyl Depot 3.75 mg for three months are reported. Subjects consisted of 12 women, among whom nine were treated for leiomyomas and four for endometriosis (one patient also had leiomyomas). Based on examinations carried out, the biggest decrease of the uterus and leiomyomas was 13-17% observed just after two doses of analog, though after the end of treatment the dimensions of the uterus slowly increased. Therefore, 2-month therapy could be used successfully as preparation for further conservative surgical treatment. Significant increase of body weight in treated patients was not observed. In women with endometriosis pain symptoms in the hypogastric area and dyspareunia regressed during treatment and at the end were not observed. The disadvantages of therapy with Decapeptyl Depot 3.75 was the rapid occurrence of symptoms--climacteric signs, especially hot flashes--which were badly tolerated by patients. All these symptoms almost totally regressed one month after ending therapy.
Szczurowicz
A
A
2nd Dept. of Obstetrics & Gynecology, Medical University of Gdansk, Poland.
Wydra
D
D
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D003692:Delayed-Action Preparations; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018231:Leiomyomatosis / Q000188:drug therapy*; D008875:Middle Aged; D017329:Triptorelin Pamoate / Q000009:adverse effects / Q000627:therapeutic use*; D014591:Uterine Diseases / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate